XenoPort, Inc. - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 44
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: X5CED9E6F9DEN
Leaflet:

Download PDF Leaflet

XenoPort, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “XenoPort, Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • XenoPort, Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of XenoPort, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of XenoPort, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the XenoPort, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate XenoPort, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of XenoPort, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the XenoPort, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with XenoPort, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of XenoPort, Inc. and identify potential opportunities in those areas.
XenoPort, Inc. Snapshot
XenoPort, Inc. Overview
Key Information
Key Facts
XenoPort, Inc. – Research and Development Overview
Key Therapeutic Areas
XenoPort, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
XenoPort, Inc. – Pipeline Products Glance
XenoPort, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
XenoPort, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
XenoPort, Inc. – Drug Profiles
XP19986
  Product Description
  Mechanism of Action
  R&D Progress
XP-21279
  Product Description
  Mechanism of Action
  R&D Progress
XP20925
  Product Description
  Mechanism of Action
  R&D Progress
XP21510
  Product Description
  Mechanism of Action
  R&D Progress
XenoPort, Inc. – Pipeline Analysis
XenoPort, Inc. – Pipeline Products by Therapeutic Class
XenoPort, Inc. Pipeline Products By Target
XenoPort, Inc. – Pipeline Products by Route of Administration
XenoPort, Inc. – Pipeline Products by Molecule Type
XenoPort, Inc. – Recent Pipeline Updates
XenoPort, Inc. – Company Statement
XenoPort, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 13, 2010: XenoPort To Present Preclinical Data Of XP23829 At ECTRIMS
Sep 28, 2010: XenoPort Announces Presentation Of New Data For XP21279 At World Parkinson Congress
Sep 13, 2010: XenoPort Announces Plans For Phase III Development Of Arbaclofen Placarbil For Spasticity
Jul 23, 2010: XenoPort To Present Preclinical Data Of Acamprosate Prodrug At Fragile X Syndrome Conference
Jun 07, 2010: XenoPort Announces Presentations Of Data For Arbaclofen Placarbil At The Associated Professional Sleep Society Meeting
May 19, 2010: Ferring Presents Findings From Two Placebo-Controlled Clinical Trials Of LYSTEDA
May 03, 2010: XenoPort Announces Presentations Of New Data For Arbaclofen Placarbil At Digestive Disease Week Meeting
May 03, 2010: XenoPort Announces Presentations Of New Data For Arbaclofen Placarbil At Digestive Disease Week Meeting
May 03, 2010: XenoPort Announces Presentations Of New Data For Arbaclofen Placarbil At Digestive Disease Week Meeting
Oct 19, 2009:
Financial Deals Landscape
XenoPort, Inc., Deals Volume Summary, 2004 to YTD 2010
XenoPort, Inc., Deals Summary By Region, 2004 to YTD 2010
XenoPort, Inc., Deals Summary, 2004 to YTD 2010
XenoPort, Inc. Detailed Deal Summary
Venture Financing
XenoPort Secures $37 Million In Financing
Equity Offering
XenoPort Completes Public Offering Of $55 Million
GlaxoSmithKline Enters Into An Agreement With XenoPort
XenoPort Enters Into A Co-Development Agreement With Pfizer
Licensing Agreements
Astellas Pharma Enters Into Licensing Agreement With XenoPort
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

XenoPort, Inc. – Pipeline by Therapy Area and Indication, 2010
XenoPort, Inc. – Pipeline by Stage of Development, 2010
XenoPort, Inc. – Monotherapy Products in Pipeline, 2010
XenoPort, Inc. - Phase II, 2010
XenoPort, Inc. - Phase I, 2010
XenoPort, Inc. - Pipeline By Therapeutic Class, 2010
XenoPort, Inc. - Pipeline By Target, 2010
XenoPort, Inc. – Pipeline By Route of Administration, 2010
XenoPort, Inc. – Pipeline By Molecule Type, 2010
XenoPort, Inc. – Recent Pipeline Updates, 2010
XenoPort, Inc., Deals Summary, 2004 to YTD 2010
XenoPort, Inc., Deals Summary by Region, 2004 to YTD 2010
XenoPort, Inc., Deals Summary, 2004 to YTD 2010 34

LIST OF FIGURES

XenoPort, Inc. – Pipeline by Therapy Area and Indication, 2010
XenoPort, Inc. – Pipeline by Stage of Development, 2010
XenoPort, Inc. – Monotherapy Products in Pipeline, 2010
XenoPort, Inc. – Pipeline By Therapeutic Class, 2010
XenoPort, Inc. - Pipeline By Target, 2010 19

Ask Your Question

XenoPort, Inc. - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: